By Nancy Lamontagne | This article originally appeared via NCBiotech’s blog
Bringing cutting-edge pharmaceuticals or medical devices to market is a complex process that can be challenging for some companies to navigate alone. To help bridge that gap, Morrisville-based Kymanox Corporation has entered into a non-exclusive collaboration with Jabil Inc., which is based in St. Petersburg, Florida, to support companies developing and commercializing drug-device combination products and other complex life science innovations.
By combining Jabil’s advanced manufacturing capabilities and global supply chain infrastructure with Kymanox’s expertise in regulatory, quality and combination products, the partnership aims to streamline commercialization and reduce development risk.
“This collaboration will allow Kymanox and Jabil to bridge gaps, such as regulatory pathway uncertainties, design verification testing needs or manufacturing capabilities, that companies might encounter as they bring their product to market,” said Nicholas Ciccarelli, Chief Technology Officer at Kymanox. “It will enhance the region’s ecosystem by fostering innovation, promoting workforce partnerships and integrating support for complex drug-device programs in the Triangle.”
The partnership will focus on supporting products, such as prefilled syringes, autoinjectors and on-body systems used to deliver small molecules, biologics and advanced therapies. It also aims to advance emerging delivery modalities for targeted organ delivery for cell and gene therapies and enable home healthcare options where precise and patient-friendly delivery systems are critical.
“Clients will benefit from leveraging the offerings from both companies that span product development, regulatory strategy, design verification and full-scale manufacturing,” said Ciccarelli. “Together, we can help clients move more efficiently from pre-clinical to commercial — ensuring that promising therapies reach patients faster.”
In February, Jabil expanded into the CDMO sector by acquiring Pharmaceutics International Inc., adding new drug product development and sterile fill-finish capabilities to its portfolio.
“Our collaboration with Kymanox takes this a step further — enabling us to offer pharmaceutical customers early-stage support with regulatory strategy and development to complement Jabil’s existing regulatory, development, commercialization, manufacturing, and packaging services,” said Mike Mahaz, SVP, Global Business Units, Healthcare, at Jabil. “Jabil and Kymanox can help pharma and biotech innovators manage complexity, accelerate timelines and deliver life-changing therapies to patients worldwide.”
According to Ciccarelli, Kymanox’s workforce continues to evolve and grow in response to client needs. “With several major pharmaceutical companies announcing new facilities in North Carolina, Kymanox is eager to support these expansion efforts — creating new opportunities to grow our own team and strengthen our presence in the region,” he said.
